Continuous PTH and PTHrP infusion causes suppression of bone formation and discordant effects on 1,25(OH)2 vitamin D.
about
PTH receptor-1 signalling-mechanistic insights and therapeutic prospectsVitamin D and Inflammatory Cytokines in Healthy and Preeclamptic PregnanciesParathyroid hormone-related protein for the treatment of postmenopausal osteoporosis: defining the maximal tolerable dose.Lactation and bone turnover: a conundrum of marked bone loss in the setting of coupled bone turnoverThe calcemic response to continuous parathyroid hormone (PTH)(1-34) infusion in end-stage kidney disease varies according to bone turnover: a potential role for PTH(7-84)The impact of dietary induced hyperparathyroidism on healthy and diseased periodontia: an experimental study in rats.A roadmap to the brittle bones of cystic fibrosis.Sustained cyclic AMP production by parathyroid hormone receptor endocytosis.Upregulation of calcitriol during pregnancy and skeletal recovery after lactation do not require parathyroid hormone.Teriparatide Therapy as an Adjuvant for Tissue Engineering and Integration of Biomaterials.A 7-day continuous infusion of PTH or PTHrP suppresses bone formation and uncouples bone turnover.Reduced parathyroid hormone-stimulated 1,25-dihydroxyvitamin d production in vitamin d sufficient postmenoposual women with low bone mass and idiopathic secondary hyperparathyroidism.The Role of Parathyroid Hormone-Related Protein (PTHrP) in Osteoblast Response to Microgravity: Mechanistic Implications for Osteoporosis Development.Parathyroid hormone-related protein: an update.Altered selectivity of parathyroid hormone (PTH) and PTH-related protein (PTHrP) for distinct conformations of the PTH/PTHrP receptor.Molecular basis of parathyroid hormone receptor signaling and trafficking: a family B GPCR paradigm.Vitamin D expenditure is not altered in pregnancy and lactation despite changes in vitamin D metabolite concentrationsProlonged signaling at the parathyroid hormone receptor by peptide ligands targeted to a specific receptor conformation.Mammary-specific ablation of the calcium-sensing receptor during lactation alters maternal calcium metabolism, milk calcium transport, and neonatal calcium accrual.A comparison of parathyroid hormone-related protein (1-36) and parathyroid hormone (1-34) on markers of bone turnover and bone density in postmenopausal women: the PrOP study.Six Weeks of Daily Abaloparatide Treatment Increased Vertebral and Femoral Bone Mineral Density, Microarchitecture and Strength in Ovariectomized Osteopenic RatsEfficacy and safety of weekly alendronate plus vitamin D₃ 5600 IU versus weekly alendronate alone in Korean osteoporotic women: 16-week randomized trialCalcium economy in human pregnancy and lactation.Bone development and mineral homeostasis in the fetus and neonate: roles of the calciotropic and phosphotropic hormones.Investigational parathyroid hormone receptor analogs for the treatment of osteoporosis.Novel targets for the prevention of osteoporosis - lessons learned from studies of metabolic bone disorders.Breast cancer cells and bone marrow mesenchymal stromal cells: a regulated modulation of the breast tumor in the context of immune response.Maternal Mineral and Bone Metabolism During Pregnancy, Lactation, and Post-Weaning Recovery.Hypercalcemia of Malignancy and Colorectal Cancer.Hypercalcemia in Lung Cancer due to Simultaneously Elevated PTHrP and Ectopic Calcitriol Production: First Case Report.Sarcoidosis-related hypercalcaemia due to production of parathyroid hormone-related peptide.Hypercalcemia of malignancy with simultaneous elevation in serum parathyroid hormone--related peptide and 1,25-dihydroxyvitamin D in a patient with metastatic renal cell carcinoma.Dual roles of parathyroid hormone related protein in TGF-β1 signaling and fibronectin up-regulation in mesangial cells.Plasma 1,25-dihydroxyvitamin D levels in primary hyperparathyroidism depend on sex, body mass index, plasma phosphate and renal function.PTH1R-CaSR Cross Talk: New Treatment Options for Breast Cancer Osteolytic Bone Metastases
P2860
Q26798005-E8D808D9-35EC-4A73-9461-328654958EE6Q26801481-F1F7C635-A055-4FB3-99DC-87347065A798Q33738711-8E12B05F-5E60-44AA-85AD-36FC764CC25FQ33786830-7AAD482B-CC17-4AB0-B498-AB1F7FC74306Q33984825-BDF5C8A5-CF9B-4A16-8EAD-72706086F06FQ34076818-FA11F0A5-A62B-4A38-A13F-F2C0B46BEACFQ34442832-8C909FB0-47A3-47E8-A24C-BA7A16D4207EQ34544553-4954B79D-74F4-48A8-9862-F15D19E7901CQ34625168-CBD9B592-E630-4377-80B3-163F79D74F7DQ35165694-8053BD3A-D91D-4904-8AB7-47DCA3C7BDDCQ35832437-B11E25AF-B5A3-4753-A8FB-5A06939878E4Q36015924-E334FC99-69BD-4964-9101-3B0E2635BC7BQ36087241-D106E193-A477-49E3-BE8B-E9CAD0A5D083Q36201545-8D45F00F-5BB1-4693-96E2-4FCF89AB90E8Q36372640-8C701DE6-3AC5-46ED-8595-972F9CB45FC9Q36599592-001332BB-A945-4A33-AB10-1D6631BDD339Q36933985-94D439E0-68B3-41C6-8B6D-D4854031F989Q36946514-6947A264-1364-4D1D-BF6F-3DADDE79321FQ37110969-86868AA0-D118-41BF-81B5-1D2D94B92555Q37213526-6730B91A-5410-4CD2-8CD3-32F1E5C6C214Q37321920-AFFDB3D3-B471-4120-9389-74DEC43CF205Q37708212-5434A2F9-001E-4194-92E1-A65594A7E3C1Q38034840-17308A79-1F32-45CD-9F31-6C75D2AC9D9DQ38257346-E20D349D-D864-415A-B543-99E3CC66015FQ38260285-7F77ED97-41C7-4FA7-8C26-D9E54D5859F3Q38470745-70AEFA7D-8B26-4E39-B415-3EA3D0722737Q38736716-6468BEFC-9B67-4CAA-B74B-4527FB3D4A93Q38737740-D5F67917-B1BF-44F3-804F-E84E019C6A4AQ38782895-C69B6905-D2A4-445D-A41D-1ABB28680877Q41023096-DB5FFF0C-3913-42C0-B7CB-E7E1F39998DEQ41111255-19FF0FF3-568C-4491-9FA5-29245309EF77Q43012875-EE112B7D-9D9A-4B2B-8553-03C0FAB12F44Q47099239-06F66887-FE37-4EDD-AF14-28EA6F8F0094Q51771792-7528F2C9-3B03-4636-B88A-0D579393B612Q57109145-3AE34B37-4DC9-4F9C-A064-084DE51CDB3B
P2860
Continuous PTH and PTHrP infusion causes suppression of bone formation and discordant effects on 1,25(OH)2 vitamin D.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Continuous PTH and PTHrP infus ...... ffects on 1,25(OH)2 vitamin D.
@ast
Continuous PTH and PTHrP infus ...... ffects on 1,25(OH)2 vitamin D.
@en
Continuous PTH and PTHrP infus ...... ffects on 1,25(OH)2 vitamin D.
@nl
type
label
Continuous PTH and PTHrP infus ...... ffects on 1,25(OH)2 vitamin D.
@ast
Continuous PTH and PTHrP infus ...... ffects on 1,25(OH)2 vitamin D.
@en
Continuous PTH and PTHrP infus ...... ffects on 1,25(OH)2 vitamin D.
@nl
prefLabel
Continuous PTH and PTHrP infus ...... ffects on 1,25(OH)2 vitamin D.
@ast
Continuous PTH and PTHrP infus ...... ffects on 1,25(OH)2 vitamin D.
@en
Continuous PTH and PTHrP infus ...... ffects on 1,25(OH)2 vitamin D.
@nl
P2093
P356
P1476
Continuous PTH and PTHrP infus ...... ffects on 1,25(OH)2 vitamin D.
@en
P2093
Adolfo Garcia-Ocaña
Alessandro Bisello
Andrew F Stewart
Bruce W Hollis
Caren Gundberg
Clifford J Rosen
John J Wysolmerski
Mara J Horwitz
Mary Beth Tedesco
Mushtaq A Syed
P304
P356
10.1359/JBMR.050602
P577
2005-06-06T00:00:00Z